Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Haematological malignancies

2506 - Impact of initial treatment (tx) on HRQoL and outcomes in patients (pts) with newly diagnosed multiple myeloma (NDMM) without intent for immediate transplant (SCT): Results from the Connect® MM registry


21 Oct 2018


Proffered paper session - Haematological malignancies


Tumour Site

Multiple Myeloma


Rafat Abonour


Annals of Oncology (2018) 29 (suppl_8): viii359-viii371. 10.1093/annonc/mdy286


R. Abonour1, R.M. Rifkin2, C. Gasparetto3, K. Toomey4, B.G..M. Durie5, J.W. Hardin6, H.R. Terebelo7, S. Jagannath8, M. Narang9, S. Ailawadhi10, S. Srinivasan11, A. Kitali12, A. Agarwal12, L. Wagner13

Author affiliations

  • 1 Hematology/oncology, Indiana University, 46202 - Indianapolis/US
  • 2 Medical Oncology / Hematology, Mountain Cancer Centers US Oncology, Denver/US
  • 3 Hematologic Malignancies And Cellular Therapy, Duke University Medical Centre, Durham/US
  • 4 Hematology And Medical Oncology, Steeplechase Cancer Center, Somerville/US
  • 5 Hematology/oncology, Cedars-Sinai Medical Center, Los Angeles/US
  • 6 Epidemiology And Biostatistics, University of South Carolina, Columbia/US
  • 7 Hematology, Providence Cancer Institute,, Novi/US
  • 8 Medicine, Hematology And Medical Oncology, Mount Sinai Hospital, New York/US
  • 9 Hematology/oncology, US Oncology Research, Columbia/US
  • 10 Hematology/oncology, Mayo Clinic, Jacksonville/US
  • 11 Biostatistics, Celgene Corporation, Summit/US
  • 12 Medical Affairs, Celgene Corporation, Summit/US
  • 13 Social Sciences & Health Policy, Wake Forest University School of Medicine, Winston-Salem/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2506


There are limited real-world longitudinal data on effects of initial tx on HRQoL in NDMM. Connect MM is a US multicenter, prospective observational cohort study designed to examine diagnostic & tx patterns, clinical outcomes & HRQoL in pts with NDMM. The aim of this analysis was to assess the role of initial tx on changes in HRQoL & outcomes in NDMM pts without intent for immediate SCT, comparing some standard EU tx regimens vs a US standard of care (lenalidomide-bortezomib-dexamethasone; RVd).


3011 NDMM pts enrolled from 250 sites; HRQoL questionnaires & clinical assessments were conducted at study baseline & quarterly (Q) until death or discontinuation (D/C). Changes in HRQoL assessments during Q1-4 of initial tx & survival outcomes (PFS & OS), adjusted for covariates through a propensity score, were examined for comparator groups: RVd vs VMP (bortezomib-melphalan-prednisone) & RVd vs Vd or VMP. Untreated pts (n = 76) or those without HRQoL assessments (n = 58) were excluded. Pts were censored by data cut off (Jan 15, 2018), transition off initial tx, progressive disease, or D/C from study.


Analysis included 1037 pts (Table); pts with VTD (n = 20) not examined due to small number. Baseline characteristics & HRQoL assessment completion rates were generally similar among groups (eg EQ-5D at Q4: 67% - 80%). There were significantly higher HRQoL improvements with RVd vs Vd or VMP for FACT-MM MMS, EQ-5D overall, & BPAIN indices. Adjusted PFS & OS were significantly longer with Table: 1007O

Changes in HRQoL ScoresRVd (n = 446) vs VMP (n = 77)RVd (n = 446) vs Vd or VMP (n = 591)
Est. diff. (95% CI)P valueEst. diff. (95% CI)P value
Total-.76 (-7.65, 6.13).833.00 (-.58, 6.58).10
TOI.69 (-5.44, 6.82).822.11 (-.74, 4.97).15
MMS1.92 (-1.29, 5.13).241.76 (.26, 3.26).02
EQ-5D overall.004 (-.04, .05).87.03 (.006, .05).02
BPAIN*-1.29 (-2.12, -0.46).002-.46 (-.82, -.09).02
Outcomes, medianRVdVMPP value; HR (95% CI)RVdVd or VMPP value; HR (95% CI)
PFS, mo29.317.5.0449; .71 (.51, .99)27.319.4.0003; .74 (.63, .87)
OS, mo62.645.6.0441; .67 (.45, .99); .73 (.60, .90)

Lower values indicate improved HRQoL, for all others higher values indicate improved HRQoL.

RVd (Table).


In this analysis of the largest US MM registry, initial tx with more efficacious RVd shows no deterioration in longitudinal HRQoL vs VMP or Vd, regimens commonly used as initial tx in the EU, & significant improvements in survival. These findings provide meaningful real-world evidence on the effects of initial tx choice on HRQoL & outcomes among pts with NDMM without intent for immediate SCT.

Clinical trial identification


Legal entity responsible for the study

Celgene Corporation.


Celgene Corporation.

Editorial Acknowledgement

The authors received editorial support from Maryann Obiorah, PhD, of Bio Connections, in the preparation of this abstract, which was funded by Celgene Corporation.


R. Abonour: Steering committee and research funding: Celgene, Takeda; Research funding: Prothena. R.M. Rifkin: Consultancy: Amgen, Boehringer Ingelheim, Celgene, EMD Serono, Sandoz, Takeda; Stock: McKesson. C. Gasparetto: Honoraria: Janssen, BMS, Celgene, Takeda; Consultancy: Janssen, BMS, Celgene; Travel, accommodations or other expenses: Janssen, BMS, Celgene; Research funding: Celgene. K. Toomey: Consultancy: Celgene; Speaker’s bureau: Myriad Genetics; Travel: Dava Oncology. B.G.M. Durie: Consultancy: Takeda, Janssen. J.W. Hardin: Consultancy: Celgene. H.R. Terebelo: Consultancy: Celgene; Speaker’s bureau: Janssen, Takeda, Pharmacyclics, S. Jagannath: Consultancy: Celgene, BMS, Novartis, Merck; Speaker’s bureau: MMRF, Medicom. M. Narang: Consultancy and speaker’s bureau: Celgene; Speaker’s bureau: Janssen. S. Ailawadhi: Consultant's fees: Takeda, Novartis, Celgene, Amgen; Research support: Pharmacyclics. S. Srinivasan, A. Kitali, A. Agarwal: Employment: Celgene. L. Wagner: Consultancy: EveryFit, Gilead, Janssen.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.